Comparison of Local Methylcobalamin and Subcutaneous Lidocaine in Subacute Herpetic Neuralgia
Comparison of Local Methylcobalamin Injection Versus Subcutaneous Lidocaine Injection in Patients With Subacute Herpetic Neuralgia
This randomized controlled trial will compare methylcobalamin and lidocaine injections for pain relief in 60 patients with subacute herpetic neuralgia over four weeks.
調査の概要
詳細な説明
This randomized controlled trial will compare the efficacy of local subcutaneous methylcobalamin injection versus subcutaneous lidocaine injection in patients aged 40-70 years with unilateral subacute herpetic neuralgia and baseline pain score greater than 6 on the visual analogue scale (VAS). A total of 60 patients will be randomly allocated to two groups, with 30 patients in each group. Group A will receive methylcobalamin injection (1 mg/2 mL), while Group B will receive lidocaine injection (1%, 2 mL), six times per week for four weeks. Pain intensity and sleep disturbance will be assessed at baseline and after 28 days of treatment. Treatment efficacy will be defined as a pain score below 3 at the end of treatment. Adverse effects will also be monitored and recorded. The study will be conducted at the Department of Dermatology, Combined Military Hospital (CMH), Multan, over six months following synopsis approval.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Punjab Province
-
Multan、Punjab Province、パキスタン、60000
- 募集
- Cmh Multan
-
コンタクト:
- HIJAB Fatima, MBBS
- 電話番号:+923359076219
- メール:hijab.fatimahf7@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
>Inclusion Criteria:
- Patients aged 40-70 years, male or female.
- Unilateral subacute herpetic neuralgia, defined as dermatomal neuropathic pain more than 30 days and up to 90 days after rash onset.
- Baseline pain score greater than 6 on the Visual Analogue Scale (VAS).
Exclusion Criteria:
- Diffuse neuropathic pain extending beyond the affected dermatome.
- Cognitive impairment.
- Use of topical agents or nerve-blocking agents within 10 days before enrolment.
- Immunocompromised patients receiving steroids at a dose of 2 mg/kg/day for more than 14 days or undergoing chemotherapy.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Methylcobalamin Injection Group
Participants will receive local subcutaneous methylcobalamin injection (1 mg/2 mL), six times per week for four weeks. |
Methylcobalamin injection (1 mg/2 mL) administered subcutaneously into up to four painful areas, with 0.5 mL injected at each area according to the patient's reported painful areas, six times per week for four weeks. |
|
アクティブコンパレータ:Lidocaine Injection Group
Participants will receive local subcutaneous lidocaine injection (1%, 2 mL), administered six times per week for four weeks. |
Lidocaine inLidocaine injection (1%, 2 mL) administered subcutaneously into up to four painful areas, with 0.5 mL injected at each area according to the patient's reported painful areas, six times per week for four weeks. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pain score
時間枠:Baseline (Day 1) and Day 28 (end of treatment).
|
Change in pain intensity measured using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (maximum bearable pain). Treatment efficacy is defined as a pain score below 3 at 28 days after randomization. |
Baseline (Day 1) and Day 28 (end of treatment).
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Sleep Disturbance Score
時間枠:Baseline (Day 1) and Day 28 (end of treatment).
|
Sleep disturbance assessed using a numeric rating scale ranging from 0 (no disturbance) to 10 (severe disturbance). |
Baseline (Day 1) and Day 28 (end of treatment).
|
|
Adverse Effects
時間枠:Throughout the 4-week treatment period (Days 1-28). with observation for one hour after each injection session.
|
Assessment and recording of adverse effects, including redness, swelling, hematoma formation, dizziness, and urticaria following injections. |
Throughout the 4-week treatment period (Days 1-28). with observation for one hour after each injection session.
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Patil A, Goldust M, Wollina U. Herpes zoster: A Review of Clinical Manifestations and Management. Viruses. 2022 Jan 19;14(2):192. doi: 10.3390/v14020192.
- Ramadhani A, Astuti I, Widiastuti MG, Purwanti N. Methylcobalamin as a candidate for chronic peripheral neuropathic pain therapy: review of molecular pharmacology actiona. Korean J Pain. 2024 Oct 1;37(4):299-309. doi: 10.3344/kjp.24171.
- Xu G, Lv ZW, Feng Y, Tang WZ, Xu GX. A single-center randomized controlled trial of local methylcobalamin injection for subacute herpetic neuralgia. Pain Med. 2013 Jun;14(6):884-94. doi: 10.1111/pme.12081. Epub 2013 Apr 8.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- File no 13/Trg--ERC No 132/26
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。